Novartis India's New Chief Has A Full Plate
Ex-AstraZeneca executive Sanjay Murdeshwar will lead Novartis in India. The incoming head faces multiple challenges including balancing profitable growth and access in a largely self-pay market.
You may also be interested in...
Novartis is planning to launch Aimovig in India after the migraine therapy was endorsed by an expert panel, but all eyes will be on pricing and how the company’s recent dispute with partner Amgen plays out.
The total cost of Zolgensma is more than $2m – in line with estimates – or $425,000 annually for five years if payers choose an annuity-like payment plan. Novartis is also negotiating value-based reimbursement agreements for infants treated with the one-time infusion.
Natco has launched a cut-price version of sacubitril/valsartan (Novartis' Entresto) on the Indian market and is also believed to have opposed the patent for the heart failure therapy.